KMT is a potential biomarker-driven metabolic therapy to lower glycolytic SLP, insulin, and oncogenic signaling below baseline, while also stabilizing the tumor microenvironment, contingent upon biological compliance and impacts from other therapies [332, 333]. The gene discussed is INS; the disease is neoplasm.